Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Debt (2020 - 2025)

Immunocore Holdings' Non-Current Debt history spans 4 years, with the latest figure at $393.1 million for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 0.54% year-over-year to $393.1 million; the TTM value through Dec 2025 reached $393.1 million, up 0.54%, while the annual FY2025 figure was $393.1 million, 0.54% up from the prior year.
  • Non-Current Debt for Q4 2025 was $393.1 million at Immunocore Holdings, roughly flat from $392.6 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $438.1 million in Q2 2024 and bottomed at $47.8 million in Q4 2022.
  • The 4-year median for Non-Current Debt is $391.8 million (2025), against an average of $332.2 million.
  • The largest annual shift saw Non-Current Debt surged 714.42% in 2024 before it fell 10.52% in 2025.
  • A 4-year view of Non-Current Debt shows it stood at $47.8 million in 2022, then increased by 0.43% to $48.0 million in 2023, then soared by 714.42% to $391.0 million in 2024, then increased by 0.54% to $393.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Non-Current Debt are $393.1 million (Q4 2025), $392.6 million (Q3 2025), and $392.1 million (Q2 2025).